Biological Assembly 1  

 3D View: Structure | 1D-3D View | Validation Report | Ligand Interaction

Global Symmetry: Cyclic - C2  (3D View)
Global Stoichiometry: Homo 2-mer - A2 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 47.05 kDa 
• Atom Count: 4439 
• Modelled Residue Count: 414 
• Deposited Residue Count: 414 
• Unique protein chains: 1

2QG0

HSP90 complexed with A943037

• PDB DOI: 10.2210/pdb2QG0/pdb

• Classification: CHAPERONE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2007-06-28 Released: 2008-07-01 
• Deposition Author(s): Park, C.H.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.85 Å
• R-Value Free: 0.285 
• R-Value Work: 0.229 
• R-Value Observed: 0.241 

Literature

Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.

Huth, J.R., Park, C., Petros, A.M., Kunzer, A.R., Wendt, M.D., Wang, X., Lynch, C.L., Mack, J.C., Swift, K.M., Judge, R.A., Chen, J., Richardson, P.L., Jin, S., Tahir, S.K., Matayoshi, E.D., Dorwin, S.A., Ladror, U.S., Severin, J.M., Walter, K.A., Bartley, D.M., Fesik, S.W., Elmore, S.W., Hajduk, P.J.

(2007) Chem Biol Drug Des 70: 1-12

• PubMed: 17630989 
• DOI: 10.1111/j.1747-0285.2007.00535.x
• Primary Citation of Related Structures:  
  2QF6, 2QFO, 2QG0, 2QG2


• PubMed Abstract: 
  

The molecular chaperone HSP90 has been shown to facilitate cancer cell survival by stabilizing key proteins responsible for a malignant phenotype. We report here the results of parallel fragment-based drug design approaches in the design of novel HSP90 inhibitors. Initial aminopyrimidine leads were elaborated using high-throughput organic synthesis to yield nanomolar inhibitors of the enzyme. Second site leads were also identified which bound to HSP90 in two distinct conformations, an 'open' and 'closed' form. Intriguingly, linked fragment approaches targeting both of these conformations were successful in producing novel, micromolar inhibitors. Overall, this study shows that, with only a few fragment hits, multiple lead series can be generated for HSP90 due to the inherent flexibility of the active site. Thus, ample opportunities exist to use these lead series in the development of clinically useful HSP90 inhibitors for the treatment of cancers.

---

Organizational Affiliation: 

Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Heat shock protein HSP 90-alpha	A, B	207	Homo sapiens	Mutation(s): 0  Gene Names: HSP90AA1, HSP90A, HSPC1, HSPCA
UniProt & NIH Common Fund Data Resources
Find proteins for P07900 (Homo sapiens) Explore P07900  Go to UniProtKB:  P07900
PHAROS:  P07900

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
A94	C [auth A], D [auth B]	N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE C17 H19 N5 O4 S VCOKUBHAJVTVNG-FMIVXFBMSA-N

Binding Affinity Annotations
ID	Source	Binding Affinity
A94	Binding MOAD:  2QG0	Ki: 1900 (nM) from 1 assay(s)
	PDBBind:  2QG0	Ki: 1900 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.85 Å
• R-Value Free: 0.285 
• R-Value Work: 0.229 
• R-Value Observed: 0.241 
• Space Group: C 1 2 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 113.346	α = 90
b = 89.144	β = 121.45
c = 64.456	γ = 90

Software Package:

Software Name	Purpose
CNX	refinement
HKL-2000	data collection
HKL-2000	data reduction
HKL-2000	data scaling
CNS	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2007-06-28 
• Released Date: 2008-07-01 
Deposition Author(s): Park, C.H.

Revision History  

• Version 1.0: 2008-07-01
  Type: Initial release
  
• Version 1.1: 2011-07-13
  Changes: Version format compliance